文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

前列腺癌根治性治疗中超大分割盆腔淋巴结照射的安全性:系统综述与Meta分析

Safety of Ultrahypofractionated Pelvic Nodal Irradiation in the Definitive Management of Prostate Cancer: Systematic Review and Meta-analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-10-19

该系统综述与Meta分析评估前列腺癌患者接受超大分割盆腔淋巴结照射的急性和晚期毒性,共纳入7项研究417例患者。盆腔淋巴结中位总剂量25 Gy(范围25-28.5 Gy),中位5次分割,前列腺中位剂量40 Gy(范围35-47.5 Gy),中位随访3年(范围0.5-5.6年)。急性≥2级胃肠和泌尿生殖毒性发生率分别为8%(95% CI 1%-15%)和29%(95% CI 18%-41%),晚期≥2级分别为13%(95% CI 5%-21%)和29%(95% CI 17%-42%)。

要点

  • 盆腔淋巴结中位总剂量25 Gy(范围25-28.5 Gy),中位5次分割。
  • 急性≥2级胃肠毒性8%(95% CI 1%-15%),泌尿生殖毒性29%(95% CI 18%-41%)。
  • 晚期≥2级胃肠毒性13%(95% CI 5%-21%),泌尿生殖毒性29%(95% CI 17%-42%)。

核心结论

  • 超大分割盆腔淋巴结照射在急性和晚期泌尿生殖及胃肠毒性方面似乎是一种安全的方法。

研究设计与样本

  • 系统综述与Meta分析,检索5个电子数据库(PubMed、Scopus、Web of Science、Cochrane Library、ClinicalTrials.gov)从建库至2023年3月23日。
  • 纳入中危、高危和淋巴结阳性前列腺癌患者接受选择性或治疗性超大分割盆腔淋巴结照射的出版物。
  • 共鉴定16篇出版物,其中7篇符合标准并纳入Meta分析,共417例患者。

主要发现

  • 盆腔淋巴结中位总剂量25 Gy(范围25-28.5 Gy),中位5次分割;前列腺中位剂量40 Gy(范围35-47.5 Gy)。
  • 所有研究均使用雄激素剥夺治疗,中位持续时间18个月;中位随访期3年(范围0.5-5.6年)。
  • 急性≥2级胃肠毒性发生率为8%(95% CI 1%-15%),急性≥2级泌尿生殖毒性为29%(95% CI 18%-41%)。
  • 晚期≥2级胃肠毒性发生率为13%(95% CI 5%-21%),晚期≥2级泌尿生殖毒性为29%(95% CI 17%-42%)。

关键数值与推荐

  • 主要结局为基于常见不良事件评价标准或放射治疗肿瘤学组量表的急性和晚期胃肠及泌尿生殖≥2级毒性发生率。
  • 质量评估使用美国国立卫生研究院针对非对照前后(单臂)临床试验及单臂观察性研究的工具。
  • 所有结局均为分类变量,计算比例以估计效应量并比较干预后结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This systematic review and meta-analysis aimed to evaluate the evidence for ultrahypofractionated pelvic nodal irradiation in patients with prostate cancer, with a focus on reported acute and late toxicities. METHODS AND MATERIALS: A comprehensive search was conducted in 5 electronic databases (PubMed, Scopus, Web of Science, Cochrane Library, ClinicalTrials.gov) from inception until March 23, 2023. Eligible publications included patients with intermediate- and high-risk and node-positive prostate cancer who underwent elective or therapeutic ultrahypofractionated pelvic nodal irradiation. Primary outcomes included the presence of grade ≥2 rates of acute and late gastrointestinal and genitourinary toxicity based on the Common Terminology Criteria for Adverse Events or Radiation Therapy Oncology Group scales. Quality assessment was performed using National Institutes of Health tools for noncontrolled beforeand after (single arm) clinical trials, as well as single-arm observational studies. Because all outcomes were categorical variables, proportion was calculated to estimate the effect size and compare the outcomes after the intervention. RESULTS: We identified 16 publications that reported the use of ultrahypofractionated radiation therapy to treat the pelvis in prostate cancer. Seven publications met our criteria and were included in the meta-analysis, including 417 patients. The median total dose to the pelvic lymph nodes was 25 Gy (range, 25-28.5 Gy), with a median of 5 fractions. The prostate received a median dose of 40 Gy (range, 35-47.5 Gy). All studies used androgen deprivation therapy for a median duration of 18 months. The median follow-up period was 3 years (range, 0.5-5.6 years). The rates of acute grade ≥2 gastrointestinal and genitourinary toxicity were 8% (95% CI, 1%-15%) and 29% (95% CI, 18%-41%), respectively. For late grade ≥2 gastrointestinal and genitourinary toxicity, the rates were 13% (95% CI, 5%-21%) and 29% (95% CI, 17%-42%), respectively. CONCLUSIONS: Ultrahypofractionated pelvic nodal irradiation appears to be a safe approach in terms of acute and late genitourinary and gastrointestinal toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mohamad O, Zamboglou C, Zilli T, et al. Safety of Ultrahypofractionated Pelvic Nodal Irradiation in the Definitive Management of Prostate Cancer: Systematic Review and Meta-analysis. Int J Radiat Oncol Biol Phys. 2023. PMID: 37863241. doi:10.1016/j.ijrobp.2023.09.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。